BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kryst J, Kawalec P, Mitoraj AM, Pilc A, Lasoń W, Brzostek T. Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials. Pharmacol Rep 2020;72:543-62. [PMID: 32301056 DOI: 10.1007/s43440-020-00097-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Zhang K, Yang Y, Yuan X, Zhang W, Han X, Lei C, Tao Z, Li Y, Liu H. Efficacy and safety of repeated esketamine intravenous infusion in the treatment of treatment-resistant depression: A case series. Asian J Psychiatr 2021;68:102976. [PMID: 34971937 DOI: 10.1016/j.ajp.2021.102976] [Reference Citation Analysis]
2 Le TT, Cordero IP, Jawad MY, Swainson J, Di Vincenzo JD, Jaberi S, Phan L, Lui LMW, Ho R, Rosenblat JD, McIntyre RS. The abuse liability of ketamine: A scoping review of preclinical and clinical studies. J Psychiatr Res 2022;151:476-96. [PMID: 35623124 DOI: 10.1016/j.jpsychires.2022.04.035] [Reference Citation Analysis]
3 Nedic Erjavec G, Sagud M, Nikolac Perkovic M, Svob Strac D, Konjevod M, Tudor L, Uzun S, Pivac N. Depression: Biological markers and treatment. Prog Neuropsychopharmacol Biol Psychiatry 2021;105:110139. [PMID: 33068682 DOI: 10.1016/j.pnpbp.2020.110139] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
4 Greenway KT, Garel N, Jerome L, Feduccia AA. Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments. Expert Review of Clinical Pharmacology 2020;13:655-70. [DOI: 10.1080/17512433.2020.1772054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Riggs LM, Gould TD. Ketamine and the Future of Rapid-Acting Antidepressants. Annu Rev Clin Psychol 2021;17:207-31. [PMID: 33561364 DOI: 10.1146/annurev-clinpsy-072120-014126] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Riggs LM, An X, Pereira EFR, Gould TD. (R,S)-ketamine and (2R,6R)-hydroxynorketamine differentially affect memory as a function of dosing frequency. Transl Psychiatry 2021;11:583. [PMID: 34772915 DOI: 10.1038/s41398-021-01685-0] [Reference Citation Analysis]
7 Altman BR, Earleywine M, De Leo J. Exploring the Credibility of Psilocybin-assisted Therapy and Cognitive-behavioral Therapy for Depression. J Psychoactive Drugs 2022;:1-9. [PMID: 34979875 DOI: 10.1080/02791072.2021.2020382] [Reference Citation Analysis]
8 Bottemanne H, Baldacci A, Muller C, Boyreau A, Claret A. [Ketamine Augmented Psychotherapy (KAP) in mood disorder: User guide]. Encephale 2021:S0013-7006(21)00224-4. [PMID: 34876279 DOI: 10.1016/j.encep.2021.08.011] [Reference Citation Analysis]
9 Ragnhildstveit A, Slayton M, Jackson LK, Brendle M, Ahuja S, Holle W, Moore C, Sollars K, Seli P, Robison R. Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions. Brain Sciences 2022;12:382. [DOI: 10.3390/brainsci12030382] [Reference Citation Analysis]
10 Małgorzata P, Paweł K, Iwona ML, Brzostek T, Andrzej P. Glutamatergic dysregulation in mood disorders: opportunities for the discovery of novel drug targets. Expert Opin Ther Targets 2020;24:1187-209. [PMID: 33138678 DOI: 10.1080/14728222.2020.1836160] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
11 Kritzer MD, Pae CU, Masand PS. Key considerations for the use of ketamine and esketamine for the treatment of depression: focusing on administration, safety, and tolerability. Expert Opin Drug Saf 2022;:1-8. [PMID: 35475388 DOI: 10.1080/14740338.2022.2069749] [Reference Citation Analysis]
12 Findeis H, Sauer C, Cleare A, Bauer M, Ritter P. Urothelial toxicity of esketamine in the treatment of depression. Psychopharmacology (Berl) 2020;237:3295-302. [PMID: 32712681 DOI: 10.1007/s00213-020-05611-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Zheng W, Zhou YL, Wang CY, Lan XF, Zhang B, Zhou SM, Yan S, Ning YP. Plasma BDNF concentrations and the antidepressant effects of six ketamine infusions in unipolar and bipolar depression. PeerJ 2021;9:e10989. [PMID: 33850645 DOI: 10.7717/peerj.10989] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Van Amsterdam J, Van Den Brink W. Harm related to recreational ketamine use and its relevance for the clinical use of ketamine. A systematic review and comparison study. Expert Opin Drug Saf 2021;:1-12. [PMID: 34176409 DOI: 10.1080/14740338.2021.1949454] [Reference Citation Analysis]
15 Li Q, Wang S, Mei X. A single intravenous administration of a sub-anesthetic ketamine dose during the perioperative period of cesarean section for preventing postpartum depression: A meta-analysis. Psychiatry Res 2022;310:114396. [PMID: 35278826 DOI: 10.1016/j.psychres.2022.114396] [Reference Citation Analysis]
16 Moldavski A, Wenz H, Lange BE, Rohleder C, Leweke FM. Case Report: Severe Adolescent Major Depressive Syndrome Turns Out to Be an Unusual Case of Anti-NMDA Receptor Encephalitis. Front Psychiatry 2021;12:679996. [PMID: 34113272 DOI: 10.3389/fpsyt.2021.679996] [Reference Citation Analysis]
17 Smith-Apeldoorn SY, Veraart JKE, Ruhé HG, Aan Het Rot M, Kamphuis J, de Boer MK, Schoevers RA. Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study. BJPsych Open 2021;8:e4. [PMID: 34865676 DOI: 10.1192/bjo.2021.1059] [Reference Citation Analysis]
18 Siodłak D, Nowak G, Mlyniec K. Interaction between zinc, the GPR39 zinc receptor and the serotonergic system in depression. Brain Res Bull 2021;170:146-54. [PMID: 33549699 DOI: 10.1016/j.brainresbull.2021.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Rizvi SJ, Gandhi W, Salomons T. Reward processing as a common diathesis for chronic pain and depression. Neurosci Biobehav Rev 2021;127:749-60. [PMID: 33951413 DOI: 10.1016/j.neubiorev.2021.04.033] [Reference Citation Analysis]
20 Dean RL, Marquardt T, Hurducas C, Spyridi S, Barnes A, Smith R, Cowen PJ, McShane R, Hawton K, Malhi GS, Geddes J, Cipriani A. Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder. Cochrane Database Syst Rev 2021;10:CD011611. [PMID: 34623633 DOI: 10.1002/14651858.CD011611.pub3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Mathai DS, McCathern AG, Guzick AG, Schneider SC, Weinzimmer SA, Cepeda SL, Garcia-Romeu A, Storch EA. Parental Attitudes Toward Use of Ketamine in Adolescent Mood Disorders and Suicidality. J Child Adolesc Psychopharmacol 2021;31:553-61. [PMID: 34665021 DOI: 10.1089/cap.2021.0078] [Reference Citation Analysis]
22 Bayes A, Short B, Zarate CA, Park L, Murrough JW, McLoughlin DM, Riva-Posse P, Schoevers R, Veraart J, Parikh S, Glue P, Fam J, McShane R, Galvez V, Martin D, Tor PC, Brunoni A, Loo CK. The Ketamine Side Effect Tool (KSET): A comprehensive measurement-based safety tool for ketamine treatment in psychiatry. J Affect Disord 2022:S0165-0327(22)00357-3. [PMID: 35405177 DOI: 10.1016/j.jad.2022.04.020] [Reference Citation Analysis]
23 Leichsenring F, Steinert C, Rabung S, Ioannidis JPA. The efficacy of psychotherapies and pharmacotherapies for mental disorders in adults: an umbrella review and meta-analytic evaluation of recent meta-analyses. World Psychiatry 2022;21:133-45. [PMID: 35015359 DOI: 10.1002/wps.20941] [Reference Citation Analysis]
24 McInnes LA, Qian JJ, Gargeya RS, DeBattista C, Heifets BD. A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings. J Affect Disord 2022;301:486-95. [PMID: 35027209 DOI: 10.1016/j.jad.2021.12.097] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
25 Chen MH, Wu HJ, Li CT, Lin WC, Tsai SJ, Hong CJ, Tu PC, Bai YM, Mao WC, Su TP. Is one or two infusions better in the first week of low-dose ketamine treatment for medication-resistant depression? A post hoc pooled analysis of randomized placebo-controlled and open-label trials. J Psychiatr Res 2021;144:448-54. [PMID: 34752941 DOI: 10.1016/j.jpsychires.2021.11.006] [Reference Citation Analysis]
26 Bayes A, Dong V, Martin D, Alonzo A, Kabourakis M, Loo C. Ketamine treatment for depression: A model of care. Aust N Z J Psychiatry 2021;:48674211039166. [PMID: 34384256 DOI: 10.1177/00048674211039166] [Reference Citation Analysis]
27 Ng J, Lui LMW, Rosenblat JD, Teopiz KM, Lipsitz O, Cha DS, Xiong J, Nasri F, Lee Y, Kratiuk K, Rodrigues NB, Gill H, Subramaniapillai M, Mansur RB, Ho R, Cao B, McIntyre RS. Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment. Psychopharmacology (Berl) 2021;238:917-26. [PMID: 33484298 DOI: 10.1007/s00213-021-05767-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
28 Carboni E, Carta AR, Carboni E, Novelli A. Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success? Front Neurosci 2021;15:657714. [PMID: 33994933 DOI: 10.3389/fnins.2021.657714] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Smith-Apeldoorn SY, Vischjager M, Veraart JK, Kamphuis J, Aan Het Rot M, Schoevers RA. The antidepressant effect and safety of non-intranasal esketamine: A systematic review. J Psychopharmacol 2022;36:531-44. [PMID: 35546042 DOI: 10.1177/02698811221084055] [Reference Citation Analysis]